未找到相关数据
Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005
被引：123
作者：
Crino, L.
Kim, D.
Riely, G. J.
Janne, P. A.
Blackhall, F. H.
Camidge, D. R.
Hirsh, V.
Mok, T.
Solomon, B. J.
Park, K.
Gadgeel, S. M.
Martins, R.
Han, J.
De Pas, T. M.
Bottomley, A.
Polli, A.
Petersen, J.
Tassell, V. R.
Shaw, A. T.
机构：
[1] Azienda Osped Perugia, Perugia, Italy
[2] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Christie Natl Hlth Serv Fdn Trust, Dept Med Oncol, Manchester, Lancs, England
[6] Univ Colorado Denver, Aurora, CO USA
[7] McGill Univ, Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada
[8] Prince Wales Hosp, Shatin, Hong Kong, Peoples R China
[9] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[10] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[11] Karmanos Canc Inst, Detroit, MI USA
[12] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA
[13] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea
[14] European Inst Oncol, Milan, Italy
[15] EORTC Headquarters, Brussels, Belgium
[16] Pfizer Oncol, Milan, Italy
[17] Pfizer Oncol, New York, NY USA
[18] Pfizer Inc, La Jolla, CA USA
[19] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.7514
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7514
引用
收藏
页数：1
相关论文